<DOC>
	<DOCNO>NCT00903994</DOCNO>
	<brief_summary>Open-label study conduct 2 US investigational site subject acute tendonitis bursitis shoulder , elbow , knee . Eligible subject receive treatment KTP , apply daily application site 3 consecutive day .</brief_summary>
	<brief_title>A Pilot Study Onset Action KTP , 20 % Treatment Acute Pain Associated With Tendonitis Bursitis Shoulder , Elbow Knee</brief_title>
	<detailed_description />
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Tendinopathy</mesh_term>
	<mesh_term>Bursitis</mesh_term>
	<mesh_term>Ketoprofen</mesh_term>
	<criteria>Are males female 18 year age old ( If female , must practice abstinence use medically acceptable form contraception ( e.g. , intrauterine device , hormonal birth control , double barrier method ) . For purpose study , female consider childbearing potential unless postmenopausal , biologically sterile , surgically sterile ( i.e. , hysterectomy , bilateral oophorectomy ) , undergone tubal ligation great equal one year . ) Have diagnosis acute tendonitis bursitis shoulder , elbow knee acute onset current episode 15 day precede screen visit Have average pain intensity daily activity past 24 hour rat 5 great 11point scale ( range 0 10 ) . ( If onset acute tendonitis bursitis le 24 hour screen visit , patient rate average pain intensity daily activity since time onset . ) Site personnel must reveal eligibility criterion prospective patient . Are willing discontinue use analgesic medication ( include overthecounter [ OTC ] analgesic ) except study patch . Note : Aspirin daily dose 81 mg per day cardiovascular prophylaxis allow . Have inform nature study provide write informed consent Have positive urine pregnancy test ( female childbearing potential ) pregnant lactate Have tendonitis bursitis secondary systemic inflammatory disease ( e.g. , rheumatoid arthritis , spondyloarthropathies ) , result calcification require surgery Have pharmacologic treatment ( e.g. , analgesic medication except 81mg prophylactic aspirin ) less 12 hour baseline assessment Have receive systemic corticosteroid 30 day precede screen visit ( e.g. , intraarticular , peritendinous , oral , parenteral administration ) . Nasal inhalation steroid permit . Have receive pharmacologic treatment physical therapy past 6 month joint target study . Pharmacologic treatment physical therapy current tendonitis bursitis allow unless medication therapy prohibit protocol . Require continue use immobilization device treatment current episode tendonitis bursitis Have history physical examination find incompatible safe participation study , include GI ulcer bleeding , anemia prolong bleeding time Have history , physical examination finding , incompatible study product use obtain robustly interpretable data , chronic skin condition psoriasis , clinically significant osteoarthritis , skin lesion wound affect site Have history drug alcohol abuse Are take medication substance contraindicate due nature study medication potential drug interaction . This include : patient allergy prescription OTC product contain NSAIDs patient aspirin NSAIDs analgesic drug induce syndrome asthma , rhinitis nasal polyps patient take medication may affect clotting , example warfarin , parenteral heparin , ticlopidine ( Ticlid® ) clopidogrel ( Plavix® ) patient take lithium patient take methotrexate Are renally hepatically impaired judgment investigator base patient 's medical history available clinical laboratory information Are take sleep medication , muscle relaxant , anticonvulsant antidepressant dose stable least 3 month Receiving physical therapy tendonitis/bursitis . Ongoing , stable physical therapy condition related tendonitis/bursitis allow . Have schedule elective surgery invasive procedure period study participation Have illness concurrent condition would , opinion investigator medical monitor , make study participation unsafe would confound study result ( e.g. , inflammatory arthritis , spondyloarthropathies , fibromyalgia , currently undergo treatment chronic pain ) Have receive investigational drug product participate investigational drug study within period 30 day prior receive study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Acute Pain</keyword>
</DOC>